background gif
eni6ma

Applied scenario

Decentralized identity for clinical and manufacturing systems

Pharmaceuticals & life sciences

Illustrative ScenarioReference organization:Pfizer Inc. (PFE)

These Applied Scenarios are illustrative architectures, not case studies of customer deployments. Named organizations are reference points for sector and scale (they have not engaged ENI6MA for the work described). Outcomes are stated conditionally: what would be expected if an estate of this profile implemented the referenced Gate form factor and circuit variant under the reference architecture.

The problem as published

Global pharma estates juggle clinical, manufacturing, and patient-adjacent systems under GDPR, HIPAA, and partner access rules. Centralized identity vaults and MFA tokens create both friction and a high-value breach target when partners and contractors need time-bounded access.

How ENI6MA would apply

ENI6MA would issue partner and employee circuits with short activation windows, enforce Gate SDK middleware on trial and manufacturing APIs, and keep PII out of the proof material, envelopes bind request hashes and policy, not the underlying PHI payload beyond digests.

Expected outcomes if implemented

  • Would reduce reliance on shared partner passwords and SMS MFA for system-to-system clinical integrations.
  • Would support regional compliance reviews with per-call burn evidence rather than vault dumps.
  • Would let partners prove authorization without ENI6MA storing their reusable secrets.

Reference architecture

Gate: SDK middleware · Circuit: hybrid · Control: registry lifecycle with timed activation

Absolute mechanism claims hold under the reference architecture.

HealthcareEnterpriseIdentityPKICybersecurity

← All applied scenarios